HRP20030957A2 - USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS - Google Patents

USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Info

Publication number
HRP20030957A2
HRP20030957A2 HR20030957A HRP20030957A HRP20030957A2 HR P20030957 A2 HRP20030957 A2 HR P20030957A2 HR 20030957 A HR20030957 A HR 20030957A HR P20030957 A HRP20030957 A HR P20030957A HR P20030957 A2 HRP20030957 A2 HR P20030957A2
Authority
HR
Croatia
Prior art keywords
disorders
azulenes
thia
dibenzo
aza
Prior art date
Application number
HR20030957A
Other languages
English (en)
Inventor
Merep Mladen
Mesi Milan
Modri� Marina
Pe�i� Dijana
Ki�emet Davor
Original Assignee
Pliva-Istra�iva�ki institut d.o.o.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva-Istra�iva�ki institut d.o.o. filed Critical Pliva-Istra�iva�ki institut d.o.o.
Priority to HR20030957A priority Critical patent/HRP20030957A2/xx
Priority to EP04798734A priority patent/EP1684751B1/en
Priority to US10/595,929 priority patent/US20070078123A1/en
Priority to DE602004008960T priority patent/DE602004008960T2/de
Priority to JP2006540632A priority patent/JP2007512309A/ja
Priority to PCT/HR2004/000055 priority patent/WO2005049020A1/en
Priority to AT04798734T priority patent/ATE372771T1/de
Priority to ES04798734T priority patent/ES2291960T3/es
Publication of HRP20030957A2 publication Critical patent/HRP20030957A2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030957A 2003-11-21 2003-11-21 USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS HRP20030957A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
HR20030957A HRP20030957A2 (en) 2003-11-21 2003-11-21 USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
EP04798734A EP1684751B1 (en) 2003-11-21 2004-11-19 Use of 1-thia-dibenzo e,h azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
US10/595,929 US20070078123A1 (en) 2003-11-21 2004-11-19 1-Thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
DE602004008960T DE602004008960T2 (de) 2003-11-21 2004-11-19 Verwendung von 1-thiadibenzo e,h azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
JP2006540632A JP2007512309A (ja) 2003-11-21 2004-11-19 中枢神経系の疾患及び障害の治療及び予防用医薬製剤を製造するための1−チア−3−アザ−ジベンゾ[e,h]アズレン類の使用
PCT/HR2004/000055 WO2005049020A1 (en) 2003-11-21 2004-11-19 Use of 1-thia-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
AT04798734T ATE372771T1 (de) 2003-11-21 2004-11-19 Verwendung von 1-thiadibenzo e,h azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
ES04798734T ES2291960T3 (es) 2003-11-21 2004-11-19 Uso de 1-tia-dibenzo-e,h-azulenos para la fabricacion de formulaciones farmaceuticas para el tratamiento y la prevencion de enfermedades y trrantorno del sistema nervioso central.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20030957A HRP20030957A2 (en) 2003-11-21 2003-11-21 USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Publications (1)

Publication Number Publication Date
HRP20030957A2 true HRP20030957A2 (en) 2005-08-31

Family

ID=34611161

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030957A HRP20030957A2 (en) 2003-11-21 2003-11-21 USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Country Status (8)

Country Link
US (1) US20070078123A1 (xx)
EP (1) EP1684751B1 (xx)
JP (1) JP2007512309A (xx)
AT (1) ATE372771T1 (xx)
DE (1) DE602004008960T2 (xx)
ES (1) ES2291960T3 (xx)
HR (1) HRP20030957A2 (xx)
WO (1) WO2005049020A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020305A8 (en) 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20030885A2 (en) * 2003-11-03 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711489A (en) * 1971-03-31 1973-01-16 Pfizer Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4198421A (en) * 1978-11-30 1980-04-15 E. I. Du Pont De Nemours And Company Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
JP3049089B2 (ja) * 1990-01-11 2000-06-05 ファルマシア・アンド・アップジョン・カンパニー 新規な中枢作用性の6,7,8,9―テトラヒドロ―3H―ベンズ[e]インドールヘテロ環式化合物
TR199801164T2 (xx) * 1996-04-12 1998-10-21 Janssen Pharmaceutica N.V. S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri.
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
HRP20020451A2 (en) * 2002-05-23 2003-12-31 Pliva D D 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof

Also Published As

Publication number Publication date
JP2007512309A (ja) 2007-05-17
ATE372771T1 (de) 2007-09-15
US20070078123A1 (en) 2007-04-05
EP1684751B1 (en) 2007-09-12
WO2005049020A1 (en) 2005-06-02
EP1684751A1 (en) 2006-08-02
DE602004008960T2 (de) 2008-06-12
DE602004008960D1 (de) 2007-10-25
ES2291960T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2004007481A3 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
HUP0300030A2 (en) Bupropion metabolites and methods of their synthesis and use and pharmaceutical compositions containing them and and their use
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
WO2005019163A3 (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
HRP20030885A2 (en) USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
NO20053673L (no) Nye antikonvulsanderivatsalter
HRP20030957A2 (en) USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
HRP20030955A2 (en) USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HK1098668A1 (en) Use of 1,3-diaza-dibenzo Äe.hÜ azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
WO2005121074A3 (en) Processes for the preparation of sertraline hydrochloride
TW200502002A (en) A new oral immediated release dosage form
HK1098670A1 (en) Use of 3-aza-1-oxa-dibenzo Äe,hÜ azulenes for the manufacture of pharmaceutical formulations for thetreatment and prevention of central nervous syste m disease and disorders
HRP20030956A2 (en) USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O.,

ODRP Renewal fee for the maintenance of a patent

Payment date: 20081111

Year of fee payment: 6

ODBI Application refused